Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 20, 2014, 08:10:57 AM

Login with username, password and session length


Members
  • Total Members: 23730
  • Latest: lume
Stats
  • Total Posts: 642744
  • Total Topics: 48891
  • Online Today: 192
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 4
Guests: 160
Total: 164

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Atripla v combivir/efavirenz study reported at IAS in Australia  (Read 2679 times)

0 Members and 1 Guest are viewing this topic.

Offline Andy Velez

  • Global Moderator
  • Member
  • Posts: 24,867
Dear All,

FYI, I received this e mail this morning:

Hello,

 

A three-year head-to-head study comparing AtriplaTM (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) components to a regimen of Combivir and efavirenz was presented today at the International AIDS Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia.

 

The study (Study 934) compares the safety and efficacy of a once-daily treatment regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Sustiva® (efavirenz), to a twice-daily regimen of Combivir® (zidovudine/ lamivudine) with Sustiva once daily.  After 144 weeks of treatment, the regimen of Truvada/Sustiva was associated with significantly greater virologic suppression compared to a Combivir-based regimen, and also caused greater increases in CD4 cell counts and fewer side effects that resulted in study discontinuation.  (Truvada and Sustiva are now available in the United States as the fixed-dose tablet, Atripla.)

 

Full details are contained in the attached press release.  Please let me know if you would like any additional information about the study.

 

Thanks you,

 

James

---
James Loduca
Public Affairs
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA   94404
p: (650) 522-5908 l f: (650) 522-5953
jloduca@gilead.com l www.gilead.com
 
Andy Velez

Offline J220

  • Member
  • Posts: 587
Re: Atripla v combivir/efavirenz study reported at IAS in Australia
« Reply #1 on: July 23, 2007, 09:35:13 AM »
Excellent, thanks for posting this. J.
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

Offline emeraldize

  • Member
  • Posts: 3,353
Re: Atripla v combivir/efavirenz study reported at IAS in Australia
« Reply #2 on: July 23, 2007, 10:45:00 AM »
Thanks Andy!

Offline vivyt

  • Member
  • Posts: 546
Re: Atripla v combivir/efavirenz study reported at IAS in Australia
« Reply #3 on: July 29, 2007, 04:27:43 PM »
I am taking Atripla and have responded very well to it. I was diagnosed 2 months ago and have been on it about that long so I can't really talk about the long term effects. I can tell you that my count has gone up and I feel MUCH better.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.